[ad_1]
Recent research to date has shown that treatment with the SARS-CoV-2 virus does not help patients entering treatment because it increases the risk of cardiac complications and, consequently, increases the risk of death.
Study data included the medical records of 96,032 patients. In four months, 14,888 of them were treated with one form or another of the antimalarial preparation chloroquine or hydroxychloroquine.
The patients were treated in 671 hospitals on six continents of the world. The study was led by researchers working at Brigham and Women’s Hospitals in Boston, USA. USA The study report was published in The Lancet.
Although it is not a randomized controlled trial, its reliability is enhanced by the relatively large number of patients with COVID-19.
The researchers analyzed the course of the disease in patients who were treated with chloroquine alone, hydroxychloroquine alone, and a combination of these drugs and a macrolide antibiotic. The macrolide group includes the antibiotic azithromycin.
The final conclusions of the study were that patients treated with any of the above combinations did not have better treatment results than other patients who had not been treated with these drugs. But for this, patients treated with chloroquine or its combinations were more likely to have abnormalities in the heartbeat.
Therefore, patients treated with the study drugs were statistically more likely to die than patients who received standard symptomatic treatment.
Of course, it should be recognized that this study, despite its scope, is not without flaws. This was a follow-up type study not characterized by randomization and double-blind control. Currently, true randomized controlled trials are also being conducted, in which neither the patient nor the treating physician knows whether he or she is receiving the study medication or the placebo.
At the start of the pandemic, the drug attracted the attention of doctors, experts, and the United States presidential administration, who were interested in the drug’s alleged antiviral properties, as it was declared effective in early March on the basis from small-scale and widely criticized studies.
And even the President of the United States, Trump, has publicly announced that he uses hydroxychloroquine on a daily basis.
It is true that the growing number of available scientific data casts doubt on the usefulness of the drug, and a clinical trial in Brazil even had to be suspended in April due to a sharp increase in mortality in patients treated with the drug.
[ad_2]
